United States Cardiology Positron Emission Tomography Scan Market

United States Cardiology Positron Emission Tomography Scan Market Size & Forecast:

• United States Cardiology Positron Emission Tomography Scan Market Size 2025: USD 344.6 Million
• United States Cardiology Positron Emission Tomography Scan Market Size 2033: USD 501.7 Million 
• United States Cardiology Positron Emission Tomography Scan Market CAGR: 4.84%
• United States Cardiology Positron Emission Tomography Scan Market Segments: By Product Type (PET Scanners, PET/CT Systems, PET/MRI Systems, Radiotracers, Imaging Software, Others), By Application (Coronary Artery Disease, Cardiac Sarcoidosis, Myocardial Viability Testing, Cardiac Perfusion Imaging, Others), By End User (Hospitals, Diagnostic Imaging Centers, Cardiology Clinics, Research Institutes, Others), By Technology (Digital PET Systems, Analog PET Systems, Hybrid Imaging Systems, AI-based Imaging Solutions, Others). 

To learn more about this report,  Download Free Sample Report

United States Cardiology Positron Emission Tomography Scan Market Summary:

The United States Cardiology Positron Emission Tomography Scan Market size is estimated at USD 344.6 Million in 2025 and is anticipated to reach USD 501.7 Million by 2033, growing at a CAGR of 4.84% from 2026 to 2033.The United States Cardiology Positron Emission Tomography (PET) Scan market still matters a lot for spotting blocked coronary arteries, gauging myocardial blood flow and figuring out if heart tissue stays viable, right before invasive cardiac procedures. In real world practice, hospitals and cardiac imaging centers lean on PET scans to reduce diagnostic fuzziness in people who have complex cardiovascular disease, especially when traditional stress testing comes back inconclusive or just doesn’t give enough clarity.

Over the past five years, the market feel shifted away from standalone imaging toward more integrated, precision cardiology workflows. PET systems are now commonly paired with AI-enabled quantification tools, and hybrid PET/CT platforms too, so clinicians can reveal ischemia sooner and move to treatment decisions faster. This movement picked up after the COVID-19 pandemic slowed elective cardiac care, and it also made the case for faster, sharper noninvasive diagnostics for high-risk patients. At the same time, reimbursement support for advanced cardiac imaging improved the adoption economics for hospitals. With cardiovascular disease prevalence rising along with obesity and diabetes rates, providers are putting more money into PET capacity in order to improve patient triage, limit needless catheterizations, and manage long term cardiac care costs more efficiently.

Key Market Insights

• The United States Cardiology Positron Emission Tomography Scan Market seems to ride on growing demand for noninvasive myocardial perfusion imaging across tertiary hospitals, and cardiac specialty centers too, kind of.
• AI-enabled PET quantification software boosted diagnostic accuracy by close to 20% from 2020 to 2025, which in turn helped push wider clinical adoption and smoother workflow efficiency, overall.
• Hybrid PET/CT systems, are leading in the industry size view , representing about 58% market share in 2025. That’s mainly because they can do more than one kind of imaging within the same session.
• Cardiac perfusion imaging still lands as the top application slice, bringing in nearly 45% revenue share. This is largely linked to rising volumes of ischemic heart disease screening.
• Myocardial blood flow quantification is the fastest-moving application segment all the way to 2032, driven by precision medicine efforts and preventive cardiology programs.
• For regions, the Northeast takes the lead in the United States Cardiology Positron Emission Tomography Scan Market, with roughly 34% share in 2025. The reason is dense hospital infrastructure in that area, and patient access.
• Meanwhile the Southern United States looks like the quickest growing regional market during the forecast, mainly due to cardiovascular disease management programs expanding, plus older populations increasing.
• On end users, hospitals stay out in front, holding around 61% market share, backed by major investments in advanced nuclear imaging infrastructure and equipment upgrades.
• Independent diagnostic imaging centers are showing the fastest growth among end-user categories, largely because outpatient cardiac screening demand keeps rising, and procedural costs can be lower.
• Rubidium-82 tracers hold a meaningful portion of the cardiology PET scan market, because they support rapid imaging and better patient throughput, which matters a lot in busy centers.

What are the Key Drivers, Restraints, and Opportunities in the United States Cardiology Positron Emission Tomography Scan Market?

The strongest driving force behind the United States Cardiology Positron Emission Tomography Scan Market is a move toward sharper cardiac diagnostics, supported by better reimbursement frameworks plus AI- enabled imaging platforms. Hospitals are more and more turning to cardiac PET scans to evaluate myocardial blood flow, with a more accurate look than older SPECT approaches, especially among obese, diabetic and high-risk cardiovascular patients. It almost feels like the main spark was revised clinical guidance, and also wider Medicare reimbursement support for advanced cardiac imaging after 2020, which basically made PET based diagnostics seem more financially livable. As providers cut back on unnecessary invasive catheterizations and even shortened the diagnostic window, hospitals then expanded PET imaging capacity, which in practice raised spending on equipment, increased radiotracer usage, and kept recurring imaging revenues moving.

The market’s most visible structural obstacle is still the steep capital and day to day operating cost tied to PET imaging infrastructure. PET/CT systems, isotope handling areas, and specialized radiopharmaceutical supply chains call for multi million dollar investments that smaller hospitals often can’t absorb as easily. This is structural because the whole market leans on regulated isotope production networks, certified nuclear medicine professionals and complicated installation requirements, which can take years to scale. So adoption tends to stay concentrated in big urban healthcare systems, and that naturally reduces how far the technology penetrates rural and mid sized care networks.

Mobile PET imaging, and AI assisted remote interpretation platforms kind of create a big growth opportunity. In places like underserved Southern and Midwestern states, healthcare providers are more and more teaming up with imaging operators who bring mobile cardiac PET services directly on site. This approach kind of reduces the infrastructure barrier s at the same time, while also widening access to advanced cardiovascular diagnostics in regions where heart disease prevalence is steadily increasing.

What Has the Impact of Artificial Intelligence Been on the United States Cardiology Positron Emission Tomography Scan Market?

Artificial intelligence along with advanced digital imaging technology are sort of reshaping the United States Cardiology Positron Emission Tomography Scan Market , mostly by making the scans more precise, automating the way images get interpreted , and improving clinical flow in day-to-day operations. AI-powered cardiac PET platforms now handle myocardial blood flow quantification , attenuation correction, and even image reconstruction steps that used to depend heavily on extensive manual review from nuclear cardiologists. Because of that, the whole scan processing time drops by something like nearly 30% in busy cardiac imaging centers , and hospitals can serve more patients without an equally proportional rise in staffing costs. 

Machine learning is also boosting predictive diagnostic ability in a more and more noticeable way. These advanced algorithms look at perfusion patterns, coronary flow reserve information, and patient history together to spot early-stage ischemia , and to forecast adverse cardiac events before symptoms become really pronounced. More hospitals are putting these forward-looking tools to work in order to triage higher-risk patients sooner, and to trim down the number of unnecessary invasive angiography procedures . Hybrid PET/CT systems , especially when they’re paired with cloud-based analytics platforms , also help operational performance by lowering the need for repeat scans while pushing higher equipment utilization rates. 

Still , one big constraint sticks around , the high integration price for AI-enabled imaging infrastructure plus interoperable data systems. Quite a few mid sized hospitals keep using older, or legacy imaging platforms, and those systems often cannot really run advanced AI software in a smooth way. That ends up slowing the adoption past major academic centers and large urban healthcare networks, even when clinicians actually do want the upgrades.

Key Market Trends 

• From 2021 to 2025, hospitals sort of sped up the switchover from stand alone PET scanners to hybrid PET/CT platforms, so they could boost diagnostic pace and also imaging accuracy, even if it was a bit messy at first.
• After the 2020 Medicare reimbursement changes, starting really soon afterward, many tertiary hospitals saw cardiac PET adoption rise, because procedural profitability looked better for those advanced nuclear imaging services, at least that’s what most teams reported.
• AI driven myocardial blood flow quantification shortened cardiac PET reading times by almost 30% across several major academic imaging centers since 2022, it kind of removed a chunk of manual review work.
• Outpatient imaging networks pushed mobile cardiac PET services through the Southern states during the post pandemic years, mainly after diagnostic backlogs revealed gaps in regional cardiovascular screening.
• GE HealthCare and Siemens Healthineers put more money into digital PET software platforms too, aiming to sharpen their competitive edge via automated cardiac analytics, and yes it was a focus in vendor roadmaps.
• Rubidium-82 tracer use went up noticeably, as providers leaned into faster imaging workflows and shorter patient turnaround times in high volume cardiac centers, which makes sense when volume is everything.
• Cardiology departments have been slowly folding PET imaging more and more into preventive care pathways , especially when diabetes and obesity related cardiovascular complications got worse after 2021, causing more early risk detection .
•  In that flow , independent diagnostic centers seemed to win bigger referral volumes from 2022 to 2025 , mostly by offering reduced price outpatient cardiac imaging options than hospitals, and in some cases with faster appointment scheduling.
• COVID era supply chain problems, during the broader disruptions, highlighted weaknesses in radiotracer distribution, so regional isotope production investments started popping up across the United States.
• Cloud connected imaging systems really gained momentum once healthcare networks wanted centralized interpretation for cardiac scans, plus multi site workflow coordination, because sending everything around manually was getting old fast.

United States Cardiology Positron Emission Tomography Scan Market Segmentation

By Product Type

PET/CT systems still seem to sit at the top of the product type landscape because most healthcare providers like these integrated imaging setups that kind of blend anatomical and functional cardiac assessment all in one, single workflow, even if the exact “single” step varies a bit. The older, traditional PET scanners are still useful for smaller diagnostic facilities, though their replacement cycles are slowly shifting toward hybrid systems, mainly for faster image reconstruction and better overall throughput .

Radiotracers like Rubidium-82 and ammonia related tracers keep commercial relevance as well, simply because the scan volumes really do depend on steady isotope availability. And on top of that, imaging software has picked up speed—hospitals are investing in AI-assisted quantification tools that cut down interpretation time. This also supports precision cardiology programs, with more consistency.

As for PET/MRI, those platforms remain mostly in the hands of research-heavy institutions , mostly due to the installation and operating cost levels, plus complexity. Looking ahead , growth will likely cluster around software-first imaging ecosystems, cloud-based analytics , and compact hybrid scanners.

Manufacturers that bundle automation, interoperability , and radiotracer logistics into one unified platform will probably strengthen their long term position with hospital networks as well as outpatient imaging operators.

To learn more about this report,  Download Free Sample Report

By Application

Cardiac perfusion imaging kind of dominates this application segment because clinicians, you know, widely use PET imaging to sort out coronary artery disease and also ischemia severity, plus myocardial blood flow evaluation. Coronary artery disease keeps generating the largest procedure volumes, mostly linked to aging demographics , diabetes prevalence and those obesity-related cardiovascular complications you see across the United States. Myocardial viability testing still plays a big part in treatment planning too, before revascularization procedures, particularly for high-risk cardiac patients. Cardiac sarcoidosis imaging stays smaller but it is expanding quickly, more like a focused niche, as advanced PET diagnostics get better at spotting inflammatory disease with higher precision. 

Demand patterns are drifting toward applications that can reduce avoidable invasive catheterization and also shorten diagnosis timelines, which clinicians really like. For the future, growth in applications will likely depend a lot on predictive cardiac analytics, preventive cardiology strategies, and more personalized treatment planning. Imaging providers that widen their quantitative perfusion analysis capacity along with AI-supported risk assessment workflows should build stronger referral relationships with cardiology departments, and integrated healthcare systems too.

By End-User

Hospitals kinda dominate the end-user segment, mainly because big health systems have the infrastructure, easy access to radiopharmaceuticals, and the specialist staffing that advanced nuclear cardiology imaging needs. Academic medical centers and tertiary hospitals still seem to lead the way in adopting hybrid imaging systems plus AI- enabled workflow platforms, largely due to the sheer cardiovascular patient volume. 

Diagnostic imaging centers are showing up as the fastest-growing end-user category, since outpatient cardiac imaging demand grew a lot after the procedure delays tied to the pandemic. Cardiology clinics also pushed more PET imaging referrals, as preventive cardiovascular screening is becoming more built into chronic disease management programs. Research institutes stay involved in tracer development, imaging software validation, and clinical trial work, even if their overall revenue input remains smaller than provider based segments. Looking ahead, the market direction points toward more decentralization, with outpatient and regional imaging networks taking a bigger share. Equipment vendors and radiotracer suppliers will likely focus more on flexible financing and mobile imaging solutions, to reach those mid-sized healthcare providers.

By Technology

Hybrid imaging systems, uh, currently kinda dominate the tech segment because hospitals really want platforms that can show metabolic and anatomical visualization in one single patient session. Digital PET systems, over the past five years, picked up serious momentum since they offer better sensitivity, faster acquisition times, and lower radiation exposure than their analog counterparts. Analog PET is still running in older healthcare facilities, but the replacement demand keeps drifting toward digitally enabled infrastructure, especially with AI-assisted image processing ideas. 

Now, AI based imaging solutions seem to affect purchase decisions in a more direct way, since many healthcare organizations are chasing workflow automation, predictive diagnostics, and more centralized image interpretation across multi-site networks. Cloud enabled analytics and remote collaboration tools have also helped a lot with day to day operational efficiency, for bigger imaging providers. Looking ahead, the competition in future technology will probably revolve around tighter software integration, automation accuracy, and interoperability with electronic health records. Firms that can blend digital imaging hardware with scalable AI platforms should gain stronger recurring revenue, because subscription based clinical software ecosystems are becoming the norm.

What are the Key Use Cases Driving the United States Cardiology Positron Emission Tomography Scan Market?

Cardiac perfusion imaging still ends up being the main reason hospitals buy and adopt cardiac PET systems, especially big centers and tertiary care places. In practice cardiologists lean on PET scans to spot coronary artery disease, figure out myocardial blood flow, and avoid unnecessary invasive angiography in those higher-risk patients , you know.

More and more diagnostic imaging centers and cardiology clinics are also using PET for myocardial viability testing, plus inflammatory heart disease assessment , especially among diabetic and obese patient groups. Academic hospitals have even widened their cardiac sarcoidosis imaging programs too, mainly because newer PET tracers made it easier to catch these inflammatory cardiac situations earlier.

Some newer use cases are showing up as well, like AI-assisted preventive cardiology screening, and even remote image interpretation via cloud-connected imaging platforms that just send everything along. Research institutes and integrated healthcare networks are looking at PET-based predictive cardiac risk models too, in order to flag asymptomatic patients before severe cardiovascular events pop up.

Which Regions are Driving the United States Cardiology Positron Emission Tomography Scan Market Growth?

The Northeast region tends to lead the United States cardiac PET imaging scene, mainly because big academic hospitals, sort of integrated care systems, and better reimbursement arrangements back fast adoption of these high-end imaging tools. Places like New York and Boston still have pretty dense networks, for example nuclear medicine specialists, radiopharmaceutical suppliers, and tertiary cardiac care centers. There is also strong back and forth between hospitals and imaging technology companies which kind of speeds up the rollout of AI assisted cardiac diagnostics ,and hybrid PET/CT systems. All of this lets providers grow cardiovascular imaging programs at a quicker pace than other regions, while also keeping procedure volumes fairly steady and clinical use rates consistent.

The Midwest region also brings solid market revenue, but it leans on longer hospital investment rhythms and wide healthcare infrastructure coverage across both city and suburban populations. Compared with the Northeast ,the Midwest seems to depend less on research led uptake and more on day to day operational efficiency plus preventive cardiovascular care initiatives. Big nonprofit hospital groups keep, kinda gradually, boosting their outpatient cardiac imaging capacity, mostly because chronic heart disease is becoming more and more common in older populations. When payer coverage holds steady and capital spending stays disciplined , regional providers are still able to move imaging upgrades along, even if the broader healthcare budgets get squeezed for a bit.

The Southern United States seems like it’s the fastest-growing regional market, mostly because cardiovascular disease prevalence keeps climbing, the population is still swelling up, and outpatient diagnostic infrastructure is getting broader you know. A bunch of hospital networks ended up pushing cardiac imaging investment harder, after pandemic related delays , because those pauses sort of made the preventive cardiovascular screening capacity gaps feel more obvious in higher risk neighborhoods. Texas and Florida in particular saw strong migration driven healthcare demand, so hospitals felt more pressure to extend advanced imaging services. In the end, this whole growth path is opening up fairly solid opportunities for imaging equipment manufacturers, radiotracer suppliers, and mobile PET service providers focused on underserved secondary cities sometime between 2026 and 2033.

Who are the Key Players in the United States Cardiology Positron Emission Tomography Scan Market and How Do They Compete?

The competitive landscape of the United States cardiac PET imaging market still looks fairly moderately consolidated, with a small group of multinational imaging companies sorta controlling most high value hospital installations and radiopharmaceutical partnerships. In practice competition is more about imaging accuracy, workflow automation , AI enabled diagnostics, and long-term service integration, not so much price. Established manufacturers keep defending share via software upgrades, cloud connected imaging ecosystems, and multi year hospital contracts, rather than doing a lot of aggressive discounting. At the same time specialized imaging software firms and radiotracer suppliers are quietly reshaping the fight, mostly by boosting cardiac quantification capabilities and improving isotope distribution efficiency for outpatient imaging providers, which kind of changes the expectations.

GE HealthCare leans into AI assisted cardiac imaging platforms that automate myocardial blood flow analysis and reduce scan interpretation time , especially across large hospital networks. The company keeps customers longer by stitching together imaging hardware, analytics software, and service support into unified enterprise contracts, so the whole package feels… consistent. Siemens Healthineers competes with digital PET detector technology that improves sensitivity and scan speed, particularly for high volume academic medical centers. They also use strategic collaborations with research hospitals, which helps Siemens validate advanced cardiac imaging applications before a broader commercial release.

Philips Healthcare sort of centers on workflow optimization and interoperability with electronic health record systems, which seems to fit integrated care providers that are juggling multi site imaging operations without too much friction. Bracco Imaging keeps expanding by pushing radiotracer innovation, plus molecular imaging partnerships, and that combo in practice builds stronger abilities for cardiac inflammation and perfusion scanning. Cardinal Health on the other hand gets a competitive edge via a nationwide radiopharmaceutical distribution infrastructure , so hospitals and diagnostic centers can still secure dependable isotope supply even with the continuing logistics constraints that sometimes disrupt nuclear medicine networks.

Company List

• GE HealthCare
• Siemens Healthineer
• Philips Healthcare
• Canon Medical Systems
• Bracco Imaging
• Jubilant Radiopharma
• Cardinal Health
• Positron Corporation
• Mediso
• United Imaging Healthcare
• Shimadzu
• Spectrum Dynamics
• Digirad
• Fujifilm Healthcare
• Hermes Medical Solutions

Recent Development News

In April 2026, Bracco Supports New ASNC Cardiac PET Imaging Standard in the U.S.: Bracco publicly endorsed a new American Society of Nuclear Cardiology (ASNC) position statement recommending cardiac PET myocardial blood flow imaging as the preferred standard for evaluating coronary artery disease. The announcement strengthens Bracco’s position in the U.S. cardiology PET imaging ecosystem and highlights increasing clinical adoption of PET-based cardiac diagnostics.

Source: https://www.prnewswire.com

In April 2026, Bracco Imaging and NYU Langone Form Strategic PET Imaging Research Alliance:  Bracco Imaging entered a multi-year research collaboration with NYU Langone Health to advance innovation in PET/CT, MRI, and AI-enabled imaging analysis. The partnership is expected to accelerate next-generation imaging technologies relevant to cardiology and precision diagnostics in the United States healthcare market.

Source: https://www.bracco.com

What Strategic Insights Define the Future of the United States Cardiology Positron Emission Tomography Scan Market?

The United States cardiac PET imaging market is kind of structurally moving toward more decentralized , data-driven cardiovascular diagnostics over the next five to seven years. The main shift is getting traction because healthcare systems are prioritizing sooner cardiac risk detection , higher outpatient imaging efficiency, and AI-assisted clinical decisions to manage the rising costs tied to cardiovascular disease. Over time, advanced hybrid imaging platforms will increasingly act like integrated predictive care tools, not really just standalone diagnostic systems, especially inside large multi-site healthcare networks.

There is a kind of hidden risk too, and it’s not obvious at first, radiotracer supply concentration. When only a few isotope production facilities exist, plus specialized distribution networks, the whole chain becomes vulnerable to manufacturing disruptions, transportation delays, or regulatory scrutiny that hits nuclear medicine logistics. Even a relatively short supply interruption can drop imaging utilization rates and then it delays revenue generation across hospitals, and diagnostic centers as well.

On the opportunity side, there’s an emerging chance in mobile cardiac PET services. This is being supported by cloud based image interpretation platforms, especially in secondary metropolitan areas across the Southern United States. Market participants should probably focus on partnerships with regional healthcare systems and radiopharmaceutical suppliers , while also investing in scalable AI enabled imaging workflows that reduce operational complexity for mid-sized providers.

United States Cardiology Positron Emission Tomography Scan Market Report Segmentation

By Product Type

• PET Scanners
• PET/CT Systems
• PET/MRI Systems
• Radiotracers
• Imaging Software
• Others

By Application

• Coronary Artery Disease
• Cardiac Sarcoidosis
• Myocardial Viability Testing
• Cardiac Perfusion Imaging
• Others

By End User

• Hospitals
• Diagnostic Imaging Centers
• Cardiology Clinics
• Research Institutes
• Others

By Technology

• Digital PET Systems
• Analog PET Systems
• Hybrid Imaging Systems
• AI-based Imaging Solutions
• Others